Acinetobacter baumannii microbiological and phenotypic characteristics of isolates from Intensive Care Unit of the Department of Internal Medicine at the University Hospital Centre in Zagreb over a four-year period

Acinetobacter baumannii is an opportun-istic nosocomial pathogen and one of the six most important multidrug-resistant microorganisms in intensive care units (ICU). 

The aim of this study was to determine the prevalence of antimicrobial resistant A. baumannii strains in ICU. 

We analysed antibiotic susceptibility of A. baumannii isolates collected in University Hospital Centre Zagreb over a four-year period (2011-2014) based on the hospital computer system data (BIS). The data were interpreted according to Clinical and Lab-oratory Standards Institute criteria.

All strains from 2014 were found to be resistant to meropenem, which is a sig-nificant increase when compared to 1.4% in 2011 and 81.8% in 2012. The resistance rate to imipenem increased to 95.8% in 2014 from 91.4% in 2011 and 81.8% in 2012. Colistin resistance, confirmed by E test, was found only in one strain in 2013. The resistance rates of other antimicrobial agents were as follows: ampicillin/sulbac-tam 8.6% and 73.9%, netilmicin 70.6% and 83.3%, gentamicin 48.6% and 91.7%, ami-kacin 82.4% and 80.0% and ciprofloxacin 100% and 100% in 2011 and 2014 respec-tively.

Our data confirmed a multidrug-resist-ance phenotype in Acinetobacter bauman-nii strains isolated in ICU at the Clinical Hospital Centre, with a significant increase in resistance rates between 2011 and 2014 against certain antimicrobial agents in-cluding ampicilin/sulbactam and carbap-enems. 

Acinetobacter baumannii, mul-tidrug resistance, extensively drug resist-ance, nosocomial pathogen

1. Feng Lin M, Yu Lan C. Antimicrobial resistance in Acinetobacter baumannii: From bench to bedside. World J Clin Cases. 2014; 2(12):787-814.

2. Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: A sys-tematic review of matched cohort and case-control studies. Crit Care. 2006;10: R48.

3. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: Multidrug-resistant Acinetobacter baumannii. Nat Rev Mi-crobiol. 2007;5:939-951.

4. Lee JC, Koerten H, van den Broek P, et al. Adherence of Acinetobacter baumannii strains to human bronchial epithelial cells. Res Microbiol. 2006;157:360.

5. Esterly J, Richardson CL, Eltoukhy NS, Qi C, Scheetz MH. Genetic Mechanisms of Antimicrobial Resistance of Acinetobacter baumannii. Ann Pharmacother. 2011.

6. Prashanth K, Badrinath S. Nosocomial infections due to Acinetobacter species: Clinical findings, risk and prognostic factors. In-dian J Med Microbiol. 2006;24:39-44.

7. Patwardhan RB, Dhakephalkar PK, Niphadkar KB, Chopade BA. A study on nosocomial pathogens in ICU with special reference to multiresistant Acinetobacter baumannii harbouring multiple plasmids. Indian J Med Res.2008;178-87.

8. Purti CT, Sunita RG, Gopal NA. Clinical and antimicrobial profile of Acinetobacter spp.: An emerging nosocomial superbug. Adv. Biomed. Res. 2014;3:13.

9. Behnia M, LoganSC, Fallen L, Catalano P. Nosocomial and ventilator-associated pneumonia in a community hospital intensive care unit: a retrospective review and analysis. BMC Research Notes. 2014;7:232

10. Gentile V, Frangipani E, Bonchi C, Minandri F, Runci F, Visca P. Iron and Acinetobacter baumannii Biofilm Formation. Pathogens. 2014;3:704-719.

11. Metan G,Pala C, Kaynar L, Cevahir F, Alp E. A nightmare for haematology clinics: extensively drug-resistant (XDR) Acinetobacter baumannii. Infez Med. 2014;1;22(4):277-82.

12. Guven T, Yilmaz G, Guner HR, Kaya Kalem A, Eser F, Tasyaran MA. Increasing resistance of nosocomial Acinetobacter bauman-nii: are we going to be defeated? Turk J Med Sci. 2014;44(1):73-8.

13. Commitee for antibiotic resistance surveillance in Croatia. Antibiotic resistance in Croatia, 2013. The Croatian Academy of Medi-cal Science. 2014.

14. Sheng WH, Liao CH, Lauderdale TL, Ko WC, Chen YS, Liu JW et al. A multicentar study of risk factors and outcome of hospital-ized patients with infections due to carbapenem-resistant Acinetobacter baumannii. Inf J Infect Dis. 2010;14:764-769.

15. Grupper M, Sprecher H, Mashich T, Finkelstein R. Attributable mortality of nosocomial Acinetobacter bacteremia. Infect Control Hosp Epidemiol. 2007;28:293-298.

16. Franolić-Kukina I, Bedenić B, Budimir A, Herljević Z, Vraneš J, Higgins P. Clonal spread of carbapenem-resistant OXA-72 positive Acinetobacter baumannii in a Croatian university hospital. Internation Journal of Infectious Diseases 2011;15:e706- e709).

17. 1Vranić-Ladavac M, Bedenić B, Minandri F, Ištok M, Frančula-Zaninović S, Ladavac R, Visca P. Carbapenem-resistance and acquired class D carbapenemases in Acinetobacter baumannii from Croatia 2009-2010. Eur J Clin Microbiol Infect Dis 2014; 33(3):471-8.